97 related articles for article (PubMed ID: 25490003)
21. The detection of quantitative serum p53 protein in lung cancer.
Sen E; Gönüllü U; Akar N
Tuberk Toraks; 2005; 53(3):231-7. PubMed ID: 16258881
[TBL] [Abstract][Full Text] [Related]
22. Biomarker identification and pathway analysis by serum metabolomics of lung cancer.
Chen Y; Ma Z; Min L; Li H; Wang B; Zhong J; Dai L
Biomed Res Int; 2015; 2015():183624. PubMed ID: 25961003
[TBL] [Abstract][Full Text] [Related]
23. Follistatin is a novel biomarker for lung adenocarcinoma in humans.
Chen F; Ren P; Feng Y; Liu H; Sun Y; Liu Z; Ge J; Cui X
PLoS One; 2014; 9(10):e111398. PubMed ID: 25347573
[TBL] [Abstract][Full Text] [Related]
24. Serum angiopoietin-2 as a clinical marker for lung cancer.
Park JH; Park KJ; Kim YS; Sheen SS; Lee KS; Lee HN; Oh YJ; Hwang SC
Chest; 2007 Jul; 132(1):200-6. PubMed ID: 17505039
[TBL] [Abstract][Full Text] [Related]
25. Evaluating the clinical significance of serum HE4 levels in lung cancer and pulmonary tuberculosis.
Liu W; Yang J; Chi PD; Zheng X; Dai SQ; Chen H; Xu BL; Liu WL
Int J Tuberc Lung Dis; 2013 Oct; 17(10):1346-53. PubMed ID: 24025389
[TBL] [Abstract][Full Text] [Related]
26. Study of interaction of GM2 activator protein with GM2 using circular dichroism and fluorescence spectroscopy.
Ravasi D; Masserini M; Vecchio G; Li YT; Li SC
Neurochem Res; 2002 Aug; 27(7-8):785-92. PubMed ID: 12374214
[TBL] [Abstract][Full Text] [Related]
27. Clinical significance of serum transforming growth factor-β1 in lung cancer.
Hou YL; Chen H; Dong ZH; Xue CJ; Wu YF; Luo HX; Wu YC; Li CH
Cancer Epidemiol; 2013 Oct; 37(5):750-3. PubMed ID: 23727122
[TBL] [Abstract][Full Text] [Related]
28. Lipoprotein(a) level and its association with tumor stage in male patients with primary lung cancer.
Yang HH; Chen XF; Hu W; Lv DQ; Ding WJ; Tang LJ; Jiang JJ; Ye MH
Clin Chem Lab Med; 2009; 47(4):452-7. PubMed ID: 19222374
[TBL] [Abstract][Full Text] [Related]
29. Pentraxin-3 is a novel biomarker of lung carcinoma.
Diamandis EP; Goodglick L; Planque C; Thornquist MD
Clin Cancer Res; 2011 Apr; 17(8):2395-9. PubMed ID: 21257721
[TBL] [Abstract][Full Text] [Related]
30. Increased serum and urinary levels of a parathyroid hormone-related protein COOH terminus in non-small cell lung cancer patients.
Nishigaki Y; Ohsaki Y; Toyoshima E; Kikuchi K
Clin Cancer Res; 1999 Jun; 5(6):1473-81. PubMed ID: 10389935
[TBL] [Abstract][Full Text] [Related]
31. Positive urinary cytology in patients with lung cancer in the absence of obvious urine tract metastases.
Voulgaris E; Pentheroudakis G; Pappa L; Bafa M; Goussia A; Dalezis P; Tsombanidou C; Geromichalos G; Papageorgiou A; Koutsilieris M; Malamou-Mitsi V; Pavlidis N
Lung Cancer; 2011 Jul; 73(1):51-8. PubMed ID: 21111510
[TBL] [Abstract][Full Text] [Related]
32. Serological investigation of the clinical significance of fascin in non-small-cell lung cancer.
Teng Y; Xu S; Yue W; Ma L; Zhang L; Zhao X; Guo Y; Zhang C; Gu M; Wang Y
Lung Cancer; 2013 Nov; 82(2):346-52. PubMed ID: 24070574
[TBL] [Abstract][Full Text] [Related]
33. Plasma CXCL14 as a Candidate Biomarker for the Diagnosis of Lung Cancer.
Tian PF; Ma YC; Yue DS; Liang F; Li CG; Chen C; Zhang H; Sun XY; Huang WH; Zhang ZF; Zhou GB; Wang GZ; Zhang B; Wang CL
Front Oncol; 2022; 12():833866. PubMed ID: 35769715
[TBL] [Abstract][Full Text] [Related]
34. Differentially expressed glycosylated patterns of α-1-antitrypsin as serum biomarkers for the diagnosis of lung cancer.
Liang Y; Ma T; Thakur A; Yu H; Gao L; Shi P; Li X; Ren H; Jia L; Zhang S; Li Z; Chen M
Glycobiology; 2015 Mar; 25(3):331-40. PubMed ID: 25347993
[TBL] [Abstract][Full Text] [Related]
35. LC-MS/MS-Based Quantitative Proteomics Analysis of Different Stages of Non-Small-Cell Lung Cancer.
Zhou M; Kong Y; Wang X; Li W; Chen S; Wang L; Wang C; Zhang Q
Biomed Res Int; 2021; 2021():5561569. PubMed ID: 33728331
[TBL] [Abstract][Full Text] [Related]
36. Tailored Synthesis of 162-Residue S-Monoglycosylated GM2-Activator Protein (GM2AP) Analogues that Allows Facile Access to a Protein Library.
Nakamura T; Sato K; Naruse N; Kitakaze K; Inokuma T; Hirokawa T; Shigenaga A; Itoh K; Otaka A
Chembiochem; 2016 Oct; 17(20):1986-1992. PubMed ID: 27428709
[TBL] [Abstract][Full Text] [Related]
37. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
38. Serum cyfra21-1 as a biomarker in patients with nonsmall cell lung cancer.
Zhao H; Shi X; Liu J; Chen Z; Wang G
J Cancer Res Ther; 2014 Nov; 10 Suppl():C215-7. PubMed ID: 25450285
[TBL] [Abstract][Full Text] [Related]
39. Interferon (alpha, beta and omega) receptor 2 is a prognostic biomarker for lung cancer.
Tanaka S; Hattori N; Ishikawa N; Horimasu Y; Deguchi N; Takano A; Tomoda Y; Yoshioka K; Fujitaka K; Arihiro K; Okada M; Yokoyama A; Kohno N
Pathobiology; 2012; 79(1):24-33. PubMed ID: 22236545
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of Annexin A2 as a novel diagnostic serum biomarker for lung cancer.
Yang J; Yang F; Nie J; Zou X; Tian H; Qin Y; Liu C
Cancer Biomark; 2015; 15(2):205-11. PubMed ID: 25519022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
